Navigating the Challenges and Growth of the 340B Program
The Medicaid Drug Rebate Program (MDRP) summit was held in Chicago, IL, from September 23 to 25, 2024. The summit focused on critical issues facing the program, including 340B participation growth, regulatory updates, legal rulings, and the concerns of pharmaceutical manufacturers.
The conference attracted over 700 participants, including industry experts in regulatory changes, government pricing, and contracting, with representation from all top 10 pharmaceutical manufacturers. While HRSA was represented, CMS was notably absent. The format included speaking sessions and panel discussions addressing the most impactful topics currently influencing MDRP, with significant attention on the 340B program and related litigation.
Results:
- The 340B Program: Discussions focused on the lack of transparency and accountability specifically relating to contract pharmacies. Manufacturers are concerned that the program’s exponential growth—from 1,000 covered entities in 1992 to over 50,000 today—indicated a deviation from the program’s initial intent, as a safety net for hospitals and clinics treating low-income patients.
- Patient Definition: A federal district court expanded the definition of a 340B patient, ruling that a prescription does not need to arise from specific services provided by the covered entity, opening the door for further program expansion.
- Bill to/Ship to Policies: Litigation such as Eli Lilly v. U.S. Department of Health and Human Services is ongoing, with potential rulings that could grant manufacturers more authority to restrict drug shipments to contract pharmacies, despite state pushback.
- 8th Circuit Ruling: The court upheld an Arkansas law prohibiting manufacturers from restricting 340B drug acquisitions and deliveries to covered entities and their contract pharmacies, marking a significant win for covered entities.
Final thoughts and recommendations:
The 340B program continues to grow at a pace that raises concerns for pharmaceutical manufacturers. Ongoing legal rulings further complicate the landscape, influencing both manufacturer policies and covered entity practices.
- Transparency and Accountability: Stakeholders should continue to work towards improving transparency in 340B pricing to ensure the program remains sustainable while benefiting low-income and uninsured patients.
- Legal Clarity: Pharmaceutical manufacturers and covered entities must monitor ongoing litigation closely, as future rulings will likely impact contract pharmacy arrangements and the scope of the 340B program.
- Strengthen Oversite: Implement more robust accounting processes to ensure adherence to the shifting 340B program requirements, while preventing potential revenue leakage from the issuance of duplicate discounts.